Glaucoma

Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.

Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.

The new service will work to reduce waiting times for glaucoma assessments, monitoring, and treatment.

If executed, the reverse merger would create a new ophthalmic company that pairs two FDA-approved technologies for use in glaucoma patients.

The retrospective cohort study included adults with POAG from 12 tertiary-care health systems participating in the SOURCE Ophthalmology Big Data consortium in the US.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.

The Preservative Freedom Coalition’s recent Glaucoma Patient Experience survey also found a need to better communication between patients and eye care providers.

The study, published in JAMA Network Open, found that only 8.2% of patients who were referred and received a glaucoma evaluation were diagnosed with glaucoma.

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous risk and help inform cost-effective methods for disease detection.

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale.

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.

Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.

Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.

Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.

Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial.

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

At Glaucoma 360 2025, Danica Marrelli, OD, FAAO, dove into the data on visual field testing for patients with glaucoma.

Attention to patients' near visual needs is warranted when choosing medications.

The CREST Registry study reported on the safety and effectiveness outcomes of microinvasive cyclodialysis clef formation with the CycloPen system, followed by scleral reinforcement with AlloFlo Bio-Tissue implantation, according to Iantrek.